Medicus Pharma’s Executive Chairman & CEO will participate in the 38th Annual Roth Conference March 22-24 in Dana Point, California. Dr. Bokhari will lead a fireside chat on March 24 at 12:30 pm PT to review the company’s clinical pipeline. A webcast of the session will be available on demand for registered attendees, and executives will hold one-on-one meetings.

The fireside chat will cover SkinJect™, a localized immuno-oncology precision product targeting non-melanoma skin diseases, especially basal cell carcinoma. The company highlights SkinJect’s potential efficacy in Gorlin Syndrome, an autosomal dominant rare disease with a market opportunity of about $2 billion. Ongoing Phase 2 studies in the US, Europe and the UAE aim to generate decision-grade data for partnering.

Dr. Bokhari is set to discuss Teverelix®, a next-generation GnRH antagonist for high-risk advanced prostate cancer and acute urinary retention relapse patients. Teverelix directly suppresses sex hormone production without a testosterone surge and offers a six-week dosing interval. This program addresses an estimated $6 billion market and is designed to improve patient compliance.

The company will outline its AI-enabled drug development strategy and Phase 2 de-risking focus. Medicus plans to advance select programs through proof-of-concept before pursuing licensing or strategic partnerships with established pharmaceutical companies. The aim is to assemble robust clinical and regulatory data to support late-stage development and commercialization agreements.